Incyte Corporation
0J9P.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.86B
Close$
$135.14
24.9% upside
Current Fair Value
24.9% upsideUndervalued by 24.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.86 Billion |
|---|---|
| Enterprise Value | $18.92 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.59 |
| Beta | 0.77 |
| Outstanding Shares | 200,378,000 |
Return
| Return on Equity | 25.41% |
|---|---|
| Return on Assets | 20.48% |
| Return on Invested Capital | 29.23% |
Valuation & Multiples
| P/E Ratio | 13.87 |
|---|---|
| PEG | 31.11 |
| Price to Sales | 3.73 |
| Price to Book Ratio | 3.49 |
| Enterprise Value to Revenue | 3.25 |
| Enterprise Value to EBIT | 9.87 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$2.20
Average shareholder expectationRevenue Estimate
$1.50 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-3.21
Average shareholder expectationRevenue Estimate
$1.47 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Incyte Corp.
2,844 employees
CEO: Paul Friedman Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (...